These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32691140)

  • 1. Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study.
    Vantaggiato L; Perruzza M; Refini RM; Bergantini L; d'Alessandro M; Cameli P; Perruzza D; Bini L; Bargagli E; Landi C
    Lung; 2020 Oct; 198(5):761-765. PubMed ID: 32691140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab.
    Landi C; Cameli P; Vantaggiato L; Bergantini L; d'Alessandro M; Perruzza M; Carleo A; Shaba E; Di Giuseppe F; Angelucci S; Bargagli E; Bini L
    Biochim Biophys Acta Proteins Proteom; 2021 Feb; 1869(2):140563. PubMed ID: 33176218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
    Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential redox proteomic profiles of serum from severe asthma patients after one month of benralizumab and mepolizumab treatment.
    Landi C; Vantaggiato L; Shaba E; Cameli P; Carleo A; d'Alessandro M; Bergantini L; Bargagli E; Bini L
    Pulm Pharmacol Ther; 2021 Oct; 70():102060. PubMed ID: 34303823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
    Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
    BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
    Hillas G; Fouka E; Papaioannou AI
    Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
    [No Abstract]   [Full Text] [Related]  

  • 9. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis.
    Ramonell RP; Iftikhar IH
    Lung; 2020 Feb; 198(1):95-103. PubMed ID: 31894410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
    Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
    BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
    Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benralizumab (Fasenra) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2018 Feb; 60(1541):33-35. PubMed ID: 29485975
    [No Abstract]   [Full Text] [Related]  

  • 14. Reslizumab (Cinqair) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
    [No Abstract]   [Full Text] [Related]  

  • 15. Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study.
    Isoyama S; Ishikawa N; Hamai K; Matsumura M; Kobayashi H; Nomura A; Ueno S; Tanimoto T; Maeda H; Iwamoto H; Hattori N
    Intern Med; 2022; 61(11):1663-1671. PubMed ID: 35650114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.
    Pelaia C; Busceti MT; Crimi C; Carpagnano GE; Lombardo N; Terracciano R; Vatrella A; Pelaia G
    Biomed Pharmacother; 2020 Sep; 129():110444. PubMed ID: 32593131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SingleNucleotide Polymorphisms as Biomarkers of Mepolizumab and Benralizumab Treatment Response in Severe Eosinophilic Asthma.
    Rojo-Tolosa S; Sánchez-Martínez JA; Caballero-Vázquez A; Pineda-Lancheros LE; González-Gutiérrez MV; Pérez-Ramírez C; Jiménez-Morales A; Morales-García C
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
    Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
    J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma].
    Zyryanov SK; Avdeev SN; Ivanov DA; Zhuravleva MV; Kniajeskaia NP; Matveev NV; Nenasheva NA; Fomina DS; Frolov MI
    Ter Arkh; 2020 Dec; 92(12):172-179. PubMed ID: 33720591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-IL-5 and anti-IL-5R biologics for severe asthma. Are there any differences in their effects?
    Granda P; Villamañán E; Carpio C; Laorden D; Quirce S; Álvarez-Sala R;
    J Asthma; 2024 Aug; 61(8):857-866. PubMed ID: 38266131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.